TCRX

TScan Therapeutics, Inc. [TCRX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TCRX Stock Summary

Top 10 Correlated ETFs

TCRX

Top 10 Correlated Stocks

TCRX

In the News

TCRX Financial details

Company Rating
-
Market Cap
337.94M
Income
-89.99M
Revenue
21.05M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
154
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-6.26
Forward P/E
-
PEG
2.09
P/S
18.53
P/B
3.31
P/C
-
P/FCF
-4.45
Quick Ratio
6.5
Current Ratio
4.68
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.92
EPS next Y
-
EPS next Q
-
EPS this Y
-50.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
85.52%
EPS Q/Q
-12.5%
-
-
-
-
SMA20
28.03%
SMA50
22.46%
SMA100
-35%
Inst Own
-
Inst Trans
-
ROA
-31%
ROE
-66%
ROC
-0.35%
Gross Margin
100%
Oper. Margin
-656%
Profit Margin
-644%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.62-9.0
52W High
-82.78%
52W Low
+55%
RSI
50.53
Rel Volume
1.18
Avg Volume
164.23K
Volume
194.53K
Perf Week
-12.92%
Perf Month
0%
Perf Quarter
-46.55%
Perf Half Y
-49.68%
-
-
-
-
Beta
0.862
-
-
Volatility
0.08%, 0.17%
Prev Close
-3.73%
Price
1.55
Change
-1.9%

Something similar

Top by Market Cap
BRH.DE
GOOG
M&M.NS
FB2A.DE
TSLA
Top Correlated ETFs
EPU
SILJ
SIL
SILV.L
GIGB.L
Top Correlated Stocks
2113.HK
7984.T
ETSY
002252.SZ
NAK
Similar Market Cap
IMPEXFERRO.NS
ALGRX
JSCP
MXHN.DE
GHL

Company Profile

Healthcare Biotechnology
  • Volume Average 164.23K
  • Market Capitalization 337.94M
  • Employee 154
  • CEO Dr. Gavin MacBeath Ph.D.
  • Headquarters Waltham,MA,US
  • IPO Date 2021-07-16
  • Website https://www.tscan.com

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.